← Human Trials & Peer-Reviewed Studies
The Glucagonotropic Effect of GIP Is Negated During Insulin-Induced Hypoglycemia in Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study
Plain-language guide to PMID 42085567 (2026): double-blind randomized controlled trial of GIP (Gastric Inhibitory Polypeptide) in 10 men.
Key Facts
- PMID
- 42085567
- Journal
- Diabetes
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Sørum NE et al. (12 authors)
- DOI
- 10.2337/db25-1128
What This Study Did, in Plain Language
What Was Tested
Researchers studied GIP (Gastric Inhibitory Polypeptide) in this randomized controlled trial publication.
In a randomized, double-blind, placebo-controlled, crossover study, 10 men with C-peptide-negative T1D participated in five experimental visits.
However, the insulin infusion suppressed glucagon to similarly low levels for all interventions.
Who Took Part
The study group was 10 men.
The age groups tagged for this paper are young adults, adults and middle-aged adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the men and researchers unaware of who received GIP (Gastric Inhibitory Polypeptide).
A placebo (an inactive look-alike) gave the GIP (Gastric Inhibitory Polypeptide) group a baseline to be compared against.
Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.
What Was Measured
However, the insulin infusion suppressed glucagon to similarly low levels for all interventions.
PubMed files the paper under topics including Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 1, Hypoglycemia, Glucagon, Insulin, Blood Glucose and Hypoglycemic Agents.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 10 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2026 (Diabetes), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.